SG10201912199XA - Anti-tim-3 antibodies and use thereof - Google Patents
Anti-tim-3 antibodies and use thereofInfo
- Publication number
- SG10201912199XA SG10201912199XA SG10201912199XA SG10201912199XA SG10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA
- Authority
- SG
- Singapore
- Prior art keywords
- tim
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016096924 | 2016-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912199XA true SG10201912199XA (en) | 2020-02-27 |
Family
ID=61246369
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
SG10201912199XA SG10201912199XA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Country Status (15)
Country | Link |
---|---|
US (3) | US11203637B2 (pt) |
EP (2) | EP3504243A4 (pt) |
JP (2) | JP6968872B2 (pt) |
KR (1) | KR102460525B1 (pt) |
CN (3) | CN116655790A (pt) |
AU (1) | AU2017317227A1 (pt) |
BR (1) | BR112019003976A2 (pt) |
CA (1) | CA3034962A1 (pt) |
EA (1) | EA201990594A1 (pt) |
MX (1) | MX2019002242A (pt) |
NZ (1) | NZ751246A (pt) |
SG (2) | SG11201901548SA (pt) |
TW (2) | TW202246347A (pt) |
WO (1) | WO2018036561A1 (pt) |
ZA (1) | ZA201901113B (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108715615B (zh) * | 2013-09-13 | 2020-11-27 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
PE20190418A1 (es) | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos |
FI3500299T3 (fi) | 2016-08-19 | 2024-02-14 | Beigene Switzerland Gmbh | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa |
WO2018036561A1 (en) | 2016-08-26 | 2018-03-01 | Beigene, Ltd. | Anti-tim-3 antibodies and use thereof |
EP3535586A4 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGUE LOBULIN AND MUCIN PROTEIN 3 (TIM-3) |
JP7118073B2 (ja) | 2017-01-09 | 2022-08-15 | テサロ, インコーポレイテッド | 抗tim-3抗体を用いてがんを処置する方法 |
EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
CN111491655A (zh) | 2017-08-07 | 2020-08-04 | 加利福尼亚大学董事会 | 用于生成安全细胞治疗剂的平台 |
WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
US20210163590A1 (en) * | 2018-03-20 | 2021-06-03 | WuXi Biologics Ireland Limited | Novel anti-tim-3 antibodies |
BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
US11807683B2 (en) | 2018-04-12 | 2023-11-07 | Nanjing Leads Biolabs Co., Ltd. | Antibody binding TIM-3 and use thereof |
MX2021001516A (es) * | 2018-08-20 | 2021-04-19 | Jiangsu Hengrui Medicine Co | Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores. |
AU2019325558A1 (en) * | 2018-08-21 | 2020-12-17 | Albert Einstein College Of Medicine | Monoclonal antibodies against human tim-3 |
KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
JP2022537411A (ja) * | 2019-06-21 | 2022-08-25 | シングル セル テクノロジー, インコーポレイテッド | 抗tim-3抗体 |
CN110498855A (zh) * | 2019-07-25 | 2019-11-26 | 钟小泉 | 一种tim-3抗体及其用途 |
AU2020387990A1 (en) * | 2019-11-21 | 2022-06-02 | Beigene, Ltd. | Methods of cancer treatment using anti-OX40 antibodies in combination with anti-TIM3 antibodies |
CN114507284B (zh) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
CN112940128A (zh) * | 2021-03-12 | 2021-06-11 | 北京广未生物科技有限公司 | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 |
EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
CN117377692A (zh) * | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | Tim-3-靶向抗体及其用途 |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024041652A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment |
WO2024041651A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies |
WO2024044675A1 (en) | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
WO2003002722A2 (en) * | 2001-06-29 | 2003-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes and methods of use thereof |
CA2474497C (en) | 2002-01-30 | 2013-12-03 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tim-3, a th1-specific cell surface molecule |
EP2212350B1 (en) | 2007-10-26 | 2013-08-28 | Governing Council of the University of Toronto | Treating chronic viral infection by targetting TIM-3 |
EP2303926A1 (en) | 2008-06-20 | 2011-04-06 | Oklahoma Medical Research Foundation | Immunogenic memapsin 2 -secretase peptides and methods of use |
ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
CN102492038B (zh) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | 抗人Tim-3的中和性单克隆抗体L3D及其用途 |
SG11201601416VA (en) * | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Novel sez6 modulators and methods of use |
CN108715615B (zh) | 2013-09-13 | 2020-11-27 | 百济神州(广州)生物科技有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
CN103721255A (zh) | 2014-01-07 | 2014-04-16 | 苏州大学 | 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途 |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN110156892B (zh) * | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
EP3212231B1 (en) | 2014-10-27 | 2021-04-28 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
KR102011205B1 (ko) * | 2014-11-06 | 2019-08-14 | 에프. 호프만-라 로슈 아게 | 항-tim3 항체 및 사용 방법 |
WO2018036561A1 (en) | 2016-08-26 | 2018-03-01 | Beigene, Ltd. | Anti-tim-3 antibodies and use thereof |
-
2017
- 2017-08-25 WO PCT/CN2017/099098 patent/WO2018036561A1/en unknown
- 2017-08-25 CA CA3034962A patent/CA3034962A1/en active Pending
- 2017-08-25 US US16/328,047 patent/US11203637B2/en active Active
- 2017-08-25 CN CN202310121523.0A patent/CN116655790A/zh active Pending
- 2017-08-25 CN CN202310121525.XA patent/CN116478290A/zh active Pending
- 2017-08-25 CN CN201780052246.5A patent/CN109790218B/zh active Active
- 2017-08-25 MX MX2019002242A patent/MX2019002242A/es unknown
- 2017-08-25 SG SG11201901548SA patent/SG11201901548SA/en unknown
- 2017-08-25 AU AU2017317227A patent/AU2017317227A1/en active Pending
- 2017-08-25 TW TW111125696A patent/TW202246347A/zh unknown
- 2017-08-25 BR BR112019003976A patent/BR112019003976A2/pt unknown
- 2017-08-25 NZ NZ751246A patent/NZ751246A/en unknown
- 2017-08-25 EP EP17842983.3A patent/EP3504243A4/en active Pending
- 2017-08-25 SG SG10201912199XA patent/SG10201912199XA/en unknown
- 2017-08-25 JP JP2019511565A patent/JP6968872B2/ja active Active
- 2017-08-25 EP EP21190971.8A patent/EP3970749A1/en active Pending
- 2017-08-25 TW TW106129066A patent/TWI769174B/zh active
- 2017-08-25 EA EA201990594A patent/EA201990594A1/ru unknown
- 2017-08-25 KR KR1020197007868A patent/KR102460525B1/ko active IP Right Grant
-
2019
- 2019-02-21 ZA ZA2019/01113A patent/ZA201901113B/en unknown
-
2021
- 2021-10-27 JP JP2021175867A patent/JP7158552B2/ja active Active
- 2021-11-15 US US17/526,817 patent/US20220135675A1/en not_active Abandoned
-
2023
- 2023-09-27 US US18/475,552 patent/US20240076375A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11203637B2 (en) | 2021-12-21 |
JP2022027659A (ja) | 2022-02-10 |
SG11201901548SA (en) | 2019-03-28 |
JP2019529373A (ja) | 2019-10-17 |
TW201819414A (zh) | 2018-06-01 |
EA201990594A1 (ru) | 2019-08-30 |
US20190276533A1 (en) | 2019-09-12 |
CN116655790A (zh) | 2023-08-29 |
CA3034962A1 (en) | 2018-03-01 |
WO2018036561A1 (en) | 2018-03-01 |
CN116478290A (zh) | 2023-07-25 |
KR102460525B1 (ko) | 2022-11-01 |
EP3504243A4 (en) | 2020-03-11 |
NZ751246A (en) | 2023-04-28 |
BR112019003976A2 (pt) | 2019-05-28 |
MX2019002242A (es) | 2019-08-16 |
TW202246347A (zh) | 2022-12-01 |
JP7158552B2 (ja) | 2022-10-21 |
AU2017317227A1 (en) | 2019-04-11 |
KR20190042037A (ko) | 2019-04-23 |
US20240076375A1 (en) | 2024-03-07 |
US20220135675A1 (en) | 2022-05-05 |
EP3504243A1 (en) | 2019-07-03 |
EP3970749A1 (en) | 2022-03-23 |
CN109790218B (zh) | 2023-03-03 |
CN109790218A (zh) | 2019-05-21 |
TWI769174B (zh) | 2022-07-01 |
ZA201901113B (en) | 2020-10-28 |
JP6968872B2 (ja) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290842A (en) | Anti-cd73 antibodies and uses thereof | |
IL268206A (en) | Antibodies directed against bcma and their use | |
SG10201912199XA (en) | Anti-tim-3 antibodies and use thereof | |
ZA202102905B (en) | Anti-galectin-9 antibodies and uses thereof | |
IL262095A (en) | Anti-pacap antibodies and their use | |
ZA202101318B (en) | Anti-phf-tau antibodies and uses thereof | |
IL268734A (en) | Anti-LAG-3 antibodies and uses thereof | |
EP3541840C0 (en) | ANTI-HLA-G ANTIBODIES AND THEIR USE | |
IL271477A (en) | Anti-cd166 antibodies and their uses | |
GB201619648D0 (en) | Novel antibodies and uses thereof | |
ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
IL269134A (en) | Antibodies against PAR2 and their use | |
IL247315A0 (en) | Anti-acth antibodies and their uses | |
IL263242A (en) | Cytosol-penetrating antibody and use thereof | |
IL272476A (en) | Anti-Apelin antibodies and their uses | |
IL266049A (en) | Antibodies against o1 and their uses | |
IL273157A (en) | Antibodies specific to AXL and their uses | |
IL271398A (en) | Anti-l1-cam antibodies and uses thereof | |
IL266082A (en) | Anti-chikv antibodies and their use | |
IL264417A (en) | Anti-o2 antibodies and their uses | |
GB201712032D0 (en) | Antibodies and uses thereof | |
SG11202003585VA (en) | Anti-vista antibody and use thereof | |
ZA201906248B (en) | Anti-ceacam1 antibody and use thereof |